Article Versions Notes

Gilham D, Smith AL, Fu L, Moore DY, Muralidharan A, Reid SPM, Stotz SC, Johansson JO, Sweeney M, Wong NCW, et al. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro. Biomedicines. 2021; 9(4):437. https://doi.org/10.3390/biomedicines9040437

Gilham, Dean, Audrey L. Smith, Li Fu, Dalia Y. Moore, Abenaya Muralidharan, St. Patrick M. Reid, Stephanie C. Stotz, Jan O. Johansson, Michael Sweeney, Norman C. W. Wong, and et al. 2021. "Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro" Biomedicines 9, no. 4: 437. https://doi.org/10.3390/biomedicines9040437

Gilham, D., Smith, A. L., Fu, L., Moore, D. Y., Muralidharan, A., Reid, S. P. M., Stotz, S. C., Johansson, J. O., Sweeney, M., Wong, N. C. W., Kulikowski, E., & El-Gamal, D. (2021). Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro. Biomedicines, 9(4), 437. https://doi.org/10.3390/biomedicines9040437